BR9807185A - Conjunto de proteìna beta amilóide isolada não fibrilar, solúvel, processos para testar os efeitos do conjunto, para proteger um animal contra diminuicões no aprendizado ou memória devido aos efeitos de um conjunto de proteìna, para reverter e para proteger uma célula nervosa, para detectar, em um material de teste, o conjunto de proteìna, para identificar compostos, para detectar ligação de receptor do conjunto de proteìna, para preparar um conjunto de proteìna beta amilóide, não fibrilar, solúvel, isolada, conjunto de proteìna, uso do mesmo, e, processo para proteger uma célula nervosa contra sinalização neuronal aberrante induzida por addl. - Google Patents
Conjunto de proteìna beta amilóide isolada não fibrilar, solúvel, processos para testar os efeitos do conjunto, para proteger um animal contra diminuicões no aprendizado ou memória devido aos efeitos de um conjunto de proteìna, para reverter e para proteger uma célula nervosa, para detectar, em um material de teste, o conjunto de proteìna, para identificar compostos, para detectar ligação de receptor do conjunto de proteìna, para preparar um conjunto de proteìna beta amilóide, não fibrilar, solúvel, isolada, conjunto de proteìna, uso do mesmo, e, processo para proteger uma célula nervosa contra sinalização neuronal aberrante induzida por addl.Info
- Publication number
- BR9807185A BR9807185A BR9807185-8A BR9807185A BR9807185A BR 9807185 A BR9807185 A BR 9807185A BR 9807185 A BR9807185 A BR 9807185A BR 9807185 A BR9807185 A BR 9807185A
- Authority
- BR
- Brazil
- Prior art keywords
- protein pool
- protect
- soluble
- effects
- nerve cell
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 5
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 102000004169 proteins and genes Human genes 0.000 title abstract 5
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title abstract 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 102000005962 receptors Human genes 0.000 title abstract 2
- 108020003175 receptors Proteins 0.000 title abstract 2
- 210000002569 neuron Anatomy 0.000 title 2
- 101100490488 Mus musculus Add3 gene Proteins 0.000 title 1
- 230000001594 aberrant effect Effects 0.000 title 1
- 230000006735 deficit Effects 0.000 title 1
- 230000003619 fibrillary effect Effects 0.000 title 1
- 230000028252 learning or memory Effects 0.000 title 1
- 230000007372 neural signaling Effects 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 abstract 3
- 102100034004 Gamma-adducin Human genes 0.000 abstract 1
- 101000799011 Homo sapiens Gamma-adducin Proteins 0.000 abstract 1
- 208000020358 Learning disease Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000033077 cellular process Effects 0.000 abstract 1
- 201000003723 learning disability Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"CONJUNTO DE PROTEìNA BETA AMILóIDE ISOLADA NãO FIBRILAR, SOLúVEL, PROCESSOS PARA TESTAR OS EFEITOS DO CONJUNTO, PARA PROTEGER UM ANIMAL CONTRA DIMINUIçõES NO APRENDIZADO OU MEMóRIA DEVIDO AOS EFEITOS DE UM CONJUNTO DE PROTEìNA, PARA REVERTER E PARA PROTEGER UMA CéLULA NERVOSA, PARA DETECTAR, EM UM MATERIAL DE TESTE, O CONJUNTO DE PROTEìNA, PARA IDENTIFICAR COMPOSTOS, PARA DETECTAR LIGAçãO DE RECEPTOR DO CONJUNTO DE PROTEìNA, PARA PREPARAR UM CONJUNTO DE PROTEìNA BELA AMILóIDE, NãO FIBRILAR, SOLúVEL, ISOLADA, CONJUNTO DE PROTEìNA, USO DO MESMO, E, PROCESSO PARA PROTEGER UMA CéLULA NERVOSA CONTRA SINALIZAçãO NEURONAL ABERRANTE INDUZIDA POR ADDL". A invenção provê ligantes de demência derivados de beta-amilóide (ADDLs) que compreende proteína amilóide reunida em estruturas oligoméricas não fibrilares, globulares, capazes de ativar os processos celulares específicos. A invenção também provê processos para testar a formação, presença, ligação de proteína de receptor e atividade celular de ADDLs, assim como compostos que bloqueiam a formação ou atividade de ADDLs, e processos para identificar estes compostos. A invenção ainda provê processos para usar ADDLs, e modular formação de ADDL e/ou atividade, inter alia, no tratamento de distúrbios de aprendizados e/ou memória.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/796,089 US6218506B1 (en) | 1997-02-05 | 1997-02-05 | Amyloid β protein (globular assembly and uses thereof) |
| PCT/US1998/002426 WO1998033815A1 (en) | 1997-02-05 | 1998-02-05 | Amyloid beta protein (globular assembly and uses thereof) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9807185A true BR9807185A (pt) | 2000-01-25 |
Family
ID=25167266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9807185-8A BR9807185A (pt) | 1997-02-05 | 1998-02-05 | Conjunto de proteìna beta amilóide isolada não fibrilar, solúvel, processos para testar os efeitos do conjunto, para proteger um animal contra diminuicões no aprendizado ou memória devido aos efeitos de um conjunto de proteìna, para reverter e para proteger uma célula nervosa, para detectar, em um material de teste, o conjunto de proteìna, para identificar compostos, para detectar ligação de receptor do conjunto de proteìna, para preparar um conjunto de proteìna beta amilóide, não fibrilar, solúvel, isolada, conjunto de proteìna, uso do mesmo, e, processo para proteger uma célula nervosa contra sinalização neuronal aberrante induzida por addl. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6218506B1 (pt) |
| EP (2) | EP1808444A1 (pt) |
| JP (2) | JP3512815B2 (pt) |
| AT (1) | ATE349467T1 (pt) |
| AU (1) | AU735825B2 (pt) |
| BR (1) | BR9807185A (pt) |
| CA (1) | CA2279555C (pt) |
| DE (1) | DE69836740T2 (pt) |
| DK (1) | DK0998495T3 (pt) |
| ES (1) | ES2280090T3 (pt) |
| PT (1) | PT998495E (pt) |
| WO (1) | WO1998033815A1 (pt) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030068316A1 (en) * | 1997-02-05 | 2003-04-10 | Klein William L. | Anti-ADDL antibodies and uses thereof |
| US20060178302A1 (en) * | 1997-02-05 | 2006-08-10 | Northwestern University & The University Of Southern California | Amyloid beta protein (globular assembly and uses thereof) |
| US6218506B1 (en) | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
| US7790856B2 (en) * | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| US6761888B1 (en) * | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US7179892B2 (en) * | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| US6787523B1 (en) * | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US20080050367A1 (en) * | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| EP1187920A2 (en) | 1999-06-09 | 2002-03-20 | Arch Development Corporation | Recombinant prion-like genes and proteins and materials and methods comprising same |
| DE60043165D1 (de) * | 1999-08-04 | 2009-11-26 | Univ Southern California | Globularer Aufbau vom Amyloid-beta- protein und deren Verwendungen |
| PE20010978A1 (es) | 1999-12-23 | 2001-09-14 | Upjohn Co | ENSAYOS Y METODOS DE DIAGNOSTICO QUE INVOLUCRAN CANALES DE SODIO COMO OBJETIVOS DE AMILOIDE ß O DE SUS AGREGADOS |
| DE1257584T1 (de) * | 2000-02-24 | 2003-05-28 | Lilly Co Eli | Humanisierte antikörper, die amyloid beta peptid demarkieren |
| EP2082749A3 (en) * | 2000-07-07 | 2010-06-30 | Bioarctic Neuroscience AB | Prevention and treatment of Alzheimer's disease |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| PE20020574A1 (es) * | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| US6815175B2 (en) * | 2001-03-16 | 2004-11-09 | Cornell Research Foundation, Inc. | Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder |
| DK1944040T3 (da) * | 2001-08-17 | 2012-10-29 | Univ Washington | Analysefremgangsmåde for Alzheimers sygdom |
| MY139983A (en) * | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| EP1545582A4 (en) * | 2002-10-01 | 2008-09-17 | Univ Northwestern | DIFFUSIBLE DERIVATIVES DERIVED FROM AMYLOID BETA (ADDL), ADDL SUBSTITUTE, ADDL BINDING MOLECULES, AND USES THEREOF |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| PL378571A1 (pl) * | 2003-02-01 | 2006-05-02 | Neuralab Limited | Czynna immunizacja dla wytworzenia przeciwciał przeciw rozpuszczalnemu A-ß |
| ATE468886T1 (de) | 2003-02-10 | 2010-06-15 | Applied Molecular Evolution | Abeta-bindende moleküle |
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| PE20050627A1 (es) | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
| US8250823B2 (en) | 2003-08-26 | 2012-08-28 | Ejot Gmbh & Co. Kg | Dowels and methods for the assembly of insulating panels |
| JP2008500286A (ja) * | 2004-05-14 | 2008-01-10 | ノースウエスタン ユニバーシティ | Ａｄｄｌ受容体を含む組成物、関連する組成物、および関連する方法 |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| US20080044356A1 (en) * | 2004-10-22 | 2008-02-21 | Regents Of The University Of Minnesota | Assemblies of Oligomeric Amyloid Beta Protein and Uses Thereof |
| US7780963B2 (en) | 2004-10-25 | 2010-08-24 | Merck & Co., Inc. | Anti-ADDL antibodies and uses thereof |
| US7625560B2 (en) * | 2004-12-15 | 2009-12-01 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| PE20061329A1 (es) * | 2004-12-15 | 2006-12-08 | Neuralab Ltd | Anticuerpos ab humanizados para mejorar la cognicion |
| TW200635608A (en) * | 2004-12-15 | 2006-10-16 | Neuralab Ltd | Aβ antibodies for use in improving cognition |
| US8420093B2 (en) | 2005-02-14 | 2013-04-16 | Merck Sharp & Dohme Corp. | Anti-ADDL monoclonal antibody and use thereof |
| US7731962B2 (en) * | 2005-02-14 | 2010-06-08 | Merck & Co., Inc. | Anti-ADDL monoclonal antibody and use thereof |
| CA2599792A1 (en) * | 2005-03-05 | 2006-09-14 | Abbott Gmbh & Co. Kg | Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies |
| JP4937143B2 (ja) * | 2005-03-05 | 2012-05-23 | アボット ゲーエムベーハー ウント カンパニー カーゲー | 非拡散性球状Ａβ（Ｘ−３８．．４３）オリゴマー構造エピトープに対して特異性を有する自己抗体を検出する方法 |
| DE102005014936A1 (de) | 2005-03-24 | 2006-12-14 | Abbott Gmbh & Co. Kg | Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung |
| WO2007016357A1 (en) * | 2005-07-29 | 2007-02-08 | Regents Of The University Of Minnesota | Amyloid beta receptor and uses thereof |
| US20080014596A1 (en) * | 2005-11-16 | 2008-01-17 | Jasna Jerecic | ADDL Binding to Hippocampal Neurons |
| JP5475994B2 (ja) * | 2005-11-30 | 2014-04-16 | アッヴィ・インコーポレイテッド | 抗Ａβグロブロマー抗体、その抗原結合部分、対応するハイブリドーマ、核酸、ベクター、宿主細胞、前記抗体を作製する方法、前記抗体を含む組成物、前記抗体の使用及び前記抗体を使用する方法。 |
| US8263558B2 (en) | 2005-11-30 | 2012-09-11 | Abbott Laboratories | Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins |
| KR101439828B1 (ko) | 2005-11-30 | 2014-09-17 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
| SG10201404801YA (en) * | 2005-12-12 | 2014-09-26 | Ac Immune Sa | Monoclonal antibody |
| NO347079B1 (no) | 2006-03-23 | 2023-05-08 | Bioarctic Neuroscience Ab | Forbedrede protofibrilselektive antistoffer og anvendelse derav |
| US8784810B2 (en) * | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| JP4876224B2 (ja) * | 2006-06-05 | 2012-02-15 | 財団法人ヒューマンサイエンス振興財団 | アミロイドβオリゴマー並びにその製造方法及び使用方法 |
| AR062065A1 (es) * | 2006-07-14 | 2008-10-15 | Ac Immune Sa | Anticuerpo humanizado |
| ES2323725T3 (es) * | 2006-07-28 | 2009-07-23 | Vista Ventures Gmbh | Procedimiento para la deteccion de oligomeros de amiloide beta en fluidos corporales. |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| AU2008206555B2 (en) * | 2007-01-18 | 2013-07-04 | Eli Lilly And Company | Pegylated Abeta Fab |
| WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| US8003097B2 (en) * | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| CN101970000A (zh) * | 2007-04-18 | 2011-02-09 | 杨森阿尔茨海默氏症免疫治疗公司 | 脑淀粉样血管病的预防和治疗 |
| SG182192A1 (en) * | 2007-06-12 | 2012-07-30 | Ac Immune Sa | Humanized antibodies to amyloid beta |
| US8048420B2 (en) * | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| US8962677B2 (en) * | 2007-07-12 | 2015-02-24 | Acumen Pharmaceuticals, Inc. | Methods of restoring cognitive ability using non-peptidic compounds |
| US9006283B2 (en) * | 2007-07-12 | 2015-04-14 | Acumen Pharmaceuticals, Inc. | Methods of modifying amyloid β oligomers using non-peptidic compounds |
| MX2010000368A (es) | 2007-07-12 | 2010-07-02 | Acumen Pharmaceuticals Inc | Metodos para modificar los oligomeros beta-amiloides usando compuestos no peptidicos. |
| US20110098309A1 (en) * | 2007-07-12 | 2011-04-28 | Acumen Pharmaceuticals, Inc. | Methods of inhibiting the formation of amyloid-beta diffusable ligands using acylhydrazide compounds |
| SI2182983T1 (sl) | 2007-07-27 | 2014-09-30 | Janssen Alzheimer Immunotherapy | Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta |
| US8932558B2 (en) * | 2007-10-05 | 2015-01-13 | Plaxgen Inc | Multi-subunit biological complexes for treatment of plaque-associated diseases |
| SG178809A1 (en) * | 2007-10-05 | 2012-03-29 | Genentech Inc | Use of anti-amyloid beta antibody in ocular diseases |
| PT2238166E (pt) * | 2007-10-05 | 2014-02-11 | Genentech Inc | Utilização do anticorpo anti-amilóide beta em doenças oculares |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US20100291071A1 (en) * | 2008-08-01 | 2010-11-18 | Immunas Pharma, Inc. | Antibody Specific Binding to A-Beta Oligomer and the Use |
| JPWO2009051220A1 (ja) * | 2007-10-19 | 2011-03-03 | イムナス・ファーマ株式会社 | Ａβオリゴマーに特異的に結合する抗体およびその利用 |
| US8993714B2 (en) * | 2007-10-26 | 2015-03-31 | Imiplex Llc | Streptavidin macromolecular adaptor and complexes thereof |
| US9217024B2 (en) | 2007-12-18 | 2015-12-22 | Acumen Pharmaceuticals, Inc. | ADDL receptor polypeptides, polynucleotides and host cells for recombinant production |
| WO2009099176A1 (ja) | 2008-02-08 | 2009-08-13 | Immunas Pharma, Inc. | Aβオリゴマーに特異的に結合する抗体およびその利用 |
| US9085614B2 (en) | 2008-08-01 | 2015-07-21 | Immunas Pharma, Inc. | Antibodies that specifically bind to Aβ oligomers and uses thereof |
| US9102526B2 (en) | 2008-08-12 | 2015-08-11 | Imiplex Llc | Node polypeptides for nanostructure assembly |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| DK2419447T3 (en) | 2009-04-17 | 2017-09-25 | Immunas Pharma Inc | ANTIBODIES THAT SPECIFICALLY BIND TO A BETA OLIGOMER AND USE THEREOF |
| US9285363B2 (en) | 2009-05-11 | 2016-03-15 | Imiplex Llc | Method of protein nanostructure fabrication |
| DK2462162T3 (en) | 2009-08-06 | 2017-01-16 | Immunas Pharma Inc | Antibodies that specifically bind to A-beta oligomers and their use |
| ES2624835T3 (es) | 2009-08-06 | 2017-07-17 | Immunas Pharma, Inc. | Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos |
| EP2463369A4 (en) | 2009-08-07 | 2013-09-18 | Kyowa Hakko Kirin Co Ltd | HUMANIZED ANTIBODIES AGAINST AMYLOID B OLIGOMERS |
| WO2011016567A1 (ja) | 2009-08-07 | 2011-02-10 | 協和発酵キリン株式会社 | 抗アミロイドβオリゴマーヒト化抗体 |
| EP2368558A1 (en) | 2010-03-23 | 2011-09-28 | Mdc Max-Delbrück-Centrum Für Molekulare Medizin Berlin - Buch | Azo compounds reducing formation and toxicity of amyloid beta aggregation intermediates |
| ES2684475T3 (es) | 2010-04-15 | 2018-10-03 | Abbvie Inc. | Proteínas que se unen a beta amiloide |
| KR101842301B1 (ko) | 2010-07-14 | 2018-03-26 | 머크 샤프 앤드 돔 코포레이션 | 항-ａｄｄｌ 모노클로날 항체 및 그의 용도 |
| US9176151B2 (en) | 2010-07-14 | 2015-11-03 | Acumen Pharmaceuticals, Inc. | Antibodies, kit and method for detecting amyloid beta oligomers |
| MX341369B (es) | 2010-07-30 | 2016-08-17 | Genentech Inc * | Anticuerpo anti-beta-amiloide humanizado seguro y funcional. |
| EP3533803B1 (en) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
| JP2014521089A (ja) | 2011-07-13 | 2014-08-25 | メルク・シャープ・アンド・ドーム・コーポレーション | 液体試料中のアミロイドベータオリゴマーの検出方法およびその使用 |
| US9377472B2 (en) | 2012-04-30 | 2016-06-28 | Amoneta Diagnostics | Biological complex specific for Alzheimer's disease detection in vitro and use thereof |
| CN106163516B (zh) | 2014-01-31 | 2019-05-28 | 考格尼申治疗股份有限公司 | 异吲哚啉组合物和治疗神经变性疾病的方法 |
| JP6628786B2 (ja) | 2014-07-10 | 2020-01-15 | バイオアークティック アーベー | 改善されたＡβプロトフィブリル結合抗体 |
| CN110869011B (zh) | 2017-05-15 | 2024-01-05 | 考格尼申治疗股份有限公司 | 用于治疗神经退行性疾病的组合物 |
| US12352719B2 (en) | 2019-09-20 | 2025-07-08 | KYCERA AVX Components Corporation | Somatic cell-based electrical biosensor |
| JPWO2024071361A1 (pt) * | 2022-09-27 | 2024-04-04 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3553592B2 (ja) | 1992-10-26 | 2004-08-11 | ビー． シェンク，デイル | 可溶性β−アミロイド・ペプチドの検出のための方法及び組成物 |
| US6218506B1 (en) | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
-
1997
- 1997-02-05 US US08/796,089 patent/US6218506B1/en not_active Expired - Lifetime
-
1998
- 1998-02-05 DK DK98905006T patent/DK0998495T3/da active
- 1998-02-05 EP EP06026771A patent/EP1808444A1/en not_active Withdrawn
- 1998-02-05 EP EP98905006A patent/EP0998495B1/en not_active Expired - Lifetime
- 1998-02-05 BR BR9807185-8A patent/BR9807185A/pt not_active Application Discontinuation
- 1998-02-05 AU AU62735/98A patent/AU735825B2/en not_active Ceased
- 1998-02-05 PT PT98905006T patent/PT998495E/pt unknown
- 1998-02-05 AT AT98905006T patent/ATE349467T1/de not_active IP Right Cessation
- 1998-02-05 JP JP53326298A patent/JP3512815B2/ja not_active Expired - Lifetime
- 1998-02-05 DE DE69836740T patent/DE69836740T2/de not_active Expired - Lifetime
- 1998-02-05 CA CA2279555A patent/CA2279555C/en not_active Expired - Lifetime
- 1998-02-05 WO PCT/US1998/002426 patent/WO1998033815A1/en not_active Ceased
- 1998-02-05 ES ES98905006T patent/ES2280090T3/es not_active Expired - Lifetime
-
2003
- 2003-10-01 JP JP2003343836A patent/JP2004091492A/ja active Pending
-
2005
- 2005-05-16 US US11/130,566 patent/US7638283B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ATE349467T1 (de) | 2007-01-15 |
| ES2280090T3 (es) | 2007-09-01 |
| WO1998033815A1 (en) | 1998-08-06 |
| DK0998495T3 (da) | 2007-05-07 |
| JP3512815B2 (ja) | 2004-03-31 |
| AU6273598A (en) | 1998-08-25 |
| EP0998495A1 (en) | 2000-05-10 |
| DE69836740D1 (de) | 2007-02-08 |
| CA2279555A1 (en) | 1998-08-06 |
| US20060166275A1 (en) | 2006-07-27 |
| PT998495E (pt) | 2007-03-30 |
| AU735825B2 (en) | 2001-07-19 |
| US6218506B1 (en) | 2001-04-17 |
| DE69836740T2 (de) | 2007-10-11 |
| EP1808444A1 (en) | 2007-07-18 |
| US7638283B2 (en) | 2009-12-29 |
| EP0998495B1 (en) | 2006-12-27 |
| JP2001501972A (ja) | 2001-02-13 |
| CA2279555C (en) | 2012-05-01 |
| JP2004091492A (ja) | 2004-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9807185A (pt) | Conjunto de proteìna beta amilóide isolada não fibrilar, solúvel, processos para testar os efeitos do conjunto, para proteger um animal contra diminuicões no aprendizado ou memória devido aos efeitos de um conjunto de proteìna, para reverter e para proteger uma célula nervosa, para detectar, em um material de teste, o conjunto de proteìna, para identificar compostos, para detectar ligação de receptor do conjunto de proteìna, para preparar um conjunto de proteìna beta amilóide, não fibrilar, solúvel, isolada, conjunto de proteìna, uso do mesmo, e, processo para proteger uma célula nervosa contra sinalização neuronal aberrante induzida por addl. | |
| AU6524500A (en) | Amyloid beta protein (globular assembly and uses thereof) | |
| Walker | Isolation from cholinergic synapses of a protein that binds to membranes in a calcium‐dependent manner | |
| DE69635740D1 (de) | Diagnose und behandlung von mit aur-1 und/oder aur-2 assoziierten erkrankungen | |
| WO1999024463A3 (en) | Signal peptide-containing proteins | |
| BR9912545A (pt) | ácidos nucleicos codificando um receptorcopulado a proteìna g envolvido em transduçãosensorial | |
| DE69122494D1 (de) | Vorrichtung zur transdermalen Applikation von Protein- oder Peptid-Medikamenten | |
| DK0948604T3 (da) | Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet | |
| ATE382366T1 (de) | Modifizierte myelin proteinmoleküle | |
| DE69001972D1 (de) | Mittel zum nachweis von gehirnkrankheiten in zusammenhang mit nervenscheidenmarkzerstoerung, insbesondere sklerosis multiplex. | |
| EA200100278A1 (ru) | Способы модулирования киназных белков множественных линий и скрининга соединений, которые модулируют киназные белки множественных линий | |
| MX14957A (es) | Nuevos derivados de tetrazol y procedimiento para su preparacion. | |
| Miao et al. | d‐Aspartate as a putative cell–cell signaling molecule in the Aplysia californica central nervous system | |
| Quitschke et al. | Specific optic nerve proteins during regeneration of the goldfish retinotectal pathway | |
| ES2151557T3 (es) | Corpusculos de proteinas de estaño, estanniocalcina. | |
| DE69433243D1 (de) | Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit | |
| WO1999033981A3 (en) | Human signal peptide-containing proteins | |
| WO1999033870A3 (en) | Human regulatory proteins | |
| Yamaguchi et al. | Calretinin, a neuronal calcium binding protein, inhibits phosphorylation of a 39 kDa synaptic membrane protein from rat brain cerebral cortex | |
| MXPA02000293A (es) | Isoformas de la amp ciclico fosfodiesterasa y metodos de uso. | |
| WO1997014966B1 (en) | Method of activating a novel ligand regulatory pathway | |
| ATE312914T1 (de) | Rdgb-proteine | |
| WO1999007849A3 (en) | Human reticulocalbin isoforms | |
| CA1340182C (en) | Method for detecting cellular pathology | |
| ATE260339T1 (de) | Antikörper gegen menschliches restrictin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR. PORTANTO, INDEFIRO O PRESENTE PEDIDO DE PATENTE COMO INVENCAO - DE ACORDO COM O ART. 8O DA LPI. |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |